patients à risque
Post on 12-Jan-2016
23 Views
Preview:
DESCRIPTION
TRANSCRIPT
Patients à risque505513
472 445 423 307 207 17469 415 367 247 161 16
00
404334
8470
––
RituximabObservation
HR = 0,55IC95 : 0,44-0,68p < 0,001
Mois
Su
rvie
san
s p
rog
ress
ion
0,8
0,6
0,4
0,2
0
1,0
60 12 24 30 42 48 6018 36 54
Observation
Rituximab maintenance
NB: Data differ slightly from published abstract
74,9 %
57,5 %
Salles GA et al. J Clin Oncol 2010;28:abstr. 8004.
Etude PRIMA
PRIMA Update: Consistent benefitacross subgroups
Favours maintenance Favours observation
Hazard ratio (HR)Subgroup
All
R-CHOPR-CVPR-FCM
CR/CRuPR
< 60≥ 60
FLIPl = 2FLIPl < 1
FLIPl > 3
FemaleMale
Category
All
Induction Chemotherapy
Response to Induction
Age
FLIPl Index
Sex
0 1 2 3
IC 95%
0,44–0,68
0,39–0,650,45–1,020,13–2,24
0,44–0,740,32–0,72
0,37–0,650,47–0,94
0,21–0,720,30–0,640,51–0,92
0,45–0,870,36–0,64
n
1018
768
28222
720291
624394
216
431370
485533
HR *
0,55
0,51
0,540,68
0,570,48
0,490,67
0,39
0,680,44
0,630,48
* Non-stratified analysis.Salles GA et al. J Clin Oncol 2010;28:abstr. 8004.
PRIMA: Conversion from PR to CR was higher with MabThera maintenance vs observation
After inductionAfter maintenance:PR patients only
CR/CRu PR PD Missing
Randomised toMabTheramaintenance
Randomised toobservation
n = 360 n = 139
n = 360 n = 152
51.8%
24.5%
18.0%
5.8%
29.6%
27.0%
38.2%
5.3%
Salles GA et al. J Clin Oncol 2010;28:abstr. 8004.
top related